Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > PSMA > PSA-HF244

FITC-Labeled Human PSMA / FOLH1 Protein, His Tag

Order Now

  • Synonym
    FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP
  • Source
    FITC-Labeled Human PSMA, His Tag (PSA-HF244) is expressed from human 293 cells (HEK293). It contains AA Lys 44 - Ala 750 (Accession # Q04609-1). It is the FITC labeled form of Human PSMA, His Tag (PSA-H52H3).
    Predicted N-terminus: His
  • Molecular Characterization
    PSMA Structure

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 81.4 KDa. The protein migrates as 85-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
  • Protein Ratio
    The FITC to protein molar ratio is 1-3.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 25 mM MES, 500 mM NaCl, pH6.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
PSMA SDS-PAGE

FITC-Labeled Human PSMA, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 PSMA ELISA

Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human PSMA, His Tag (Cat. No. PSA-HF244) with a linear range of 0.005-0.16 μg/mL (QC tested).

Bioactivity-FACS
 PSMA FACS

2e5 of Anti-PSMA CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human PSMA Protein, His Tag (Cat. No. PSA-HF244) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).

  • Background
    Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $319.00

Price(USD) : $2180.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:5 Details
  • Number of Drugs in Clinical Trials:72 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message